

# Kluwer Patent Blog

## Dosage regime claims

Derk Visser (EIP) · Thursday, April 29th, 2010

A second medical use claim can be based on a novel dosage regimen. In decision [T317/95](#) a Board of Appeal decided that this type of claim was not allowable. It regarded the activity of administering a medicine as a therapeutic treatment and, hence, an activity in a field excluded from patentability. Since the patent right must be in the industrial and commercial field, the distinguishing feature of the claim should not relate to non-commercial and non-industrial medical activities. However, closer inspection of the decision showed that the reasoning of the Board was in conflict with decision [G5/83](#) of the Enlarged Board of Appeal. In spite of this, several other decisions refused claims based on dosage regimens.

Decision [T1020/03](#) disagreed with the earlier decisions and allowed claims based on a drug regimen, showing that the earlier decisions did not follow the decision of the Enlarged Board of Appeal. Subsequently, the President of the EPO approved the use of [T1020/03](#) by the examining divisions.

Decision [T1319/04](#) has asked the Enlarged Board of Appeal to decide whether a novel dosage regimen for an otherwise known therapeutic purpose is sufficient to confer patentability on that use under the EPC 2000, since decision [T1020/03](#) was taken under the EPC 1973.

In February 2010 the Enlarged Board of Appeal has pronounced its decision [G2/08](#). It gave the following summary:

“I. Where it is already known to use a medicament to treat an illness, Article 54(5) EPC does not exclude that this medicament be patented for use in a different treatment by therapy of the same illness.

II. Such patenting is also not excluded where a dosage regime is the only feature claimed which is not comprised in the state of the art.

III. Where the subject matter of a claim is rendered novel only by a new therapeutic use of a medicament, such claim may no longer have the format of a so called Swiss-type claim as instituted by decision [G 5/83](#). Future applicants must comply with this new situation three months after publication of the decision in the Official Journal of the EPO.”

The Enlarged Board of Appeal arrived at point I of the summary by giving a broad interpretation to ‘any specific use’ in Article 54(5) EPC; the specific use need not be the treatment of another disease. A dosage regimen is not given another treatment than the one given to any other specific use acknowledged in the case law; hence, patenting is not excluded where a dosage regime is the only new feature claimed.

The Swiss-type claim directed to the use of a substance or composition for the manufacture of a medicament for a specified therapeutic application, as permitted by decision [G5/83](#), was used to fill a gap in the legal provisions of the EPC 1973. Article 54(5) EPC 2000, permitting a purpose-related product protection for any further specific use of a known medicament in a method of therapy, closes the loophole. Since the reason for the Swiss-type claim has ceased to exist, the Swiss-type claim may no longer be used.

The abolishment of the Swiss-type claim has no retroactive effect and applies only to future applications that have a date of filing or, if priority has been claimed, a priority date later than three months after publication of [G2/08](#) in the Official Journal of the EPO. At the time of writing (April 2010), the decision had not yet been published.

---

*To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please [subscribe here](#).*

## Kluwer IP Law


The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.

---

79% of the lawyers think that the importance of legal technology will increase for next year.

**Drive change with Kluwer IP Law.**  
The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT  
The Wolters Kluwer Future Ready Lawyer  
Leading change

---

This entry was posted on Thursday, April 29th, 2010 at 1:00 am and is filed under [EPC](#). You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.